RSS Feeds
Hyperlactatemia due to Nevirapine
- George Panos, MD, PhD;
- Petros Kopterides, MD; and
- Matthew E. Falagas, MD, MSc, DSc
- From 1st IKA Hospital and “Attikon” University Hospital and Alfa Institute of Biomedical Sciences, Athens, Greece, and Tufts University School of Medicine, Boston, Massachusetts.
Background: Hyperlactatemia is a well-known adverse reaction in HIV-infected patients who are treated with nucleoside analogue reverse transcriptase inhibitors (NRTIs) (1). However, data on its association with the other 2 widely used classes of antiretroviral agents, nonnucleoside reverse transcriptase inhibitors (NNRTIs) and protease inhibitors, are inconclusive. To our knowledge, no cases of hyperlactatemia secondary to nevirapine use have been reported to date.
Objective: To describe a patient with nevirapine-induced hyperlactatemia who gradually recovered after cessation of treatment.
Methods and Findings: A 36-year-old man received a diagnosis of HIV infection in November 2000 and began receiving azidothymidine–lamivudine–nevirapine in January 2001. He tolerated the treatment well for 20 months, achieving suppression of the viral load to undetectable levels and an increase in CD4+ cell count to 1.506 × 109 cells/L. He …
